Skip to content

Bromelan's effect on the pain and bleeding of Primary dysmenorrhea

Comparing effect of bromelain and Mefenamic acid on primary dysmenorrhea pain and bleeding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016112131000N1
Enrollment
90
Registered
2016-12-26
Start date
2016-12-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhoea. Primary dysmenorrhoea

Interventions

Intervention 1: The first intervention group:treated with Bromelain 250 mg every 6 hours for 2 menstrual cycle in the first three days of the menstrual cycle. Intervention 2: The second intervention g
Treatment - Drugs
The first intervention group:treated with Bromelain 250 mg every 6 hours for 2 menstrual cycle in the first three days of the menstrual cycle
The second intervention group: treated with mefenamic acid 250 mg every 6 hours for 2 menstrual cycle in the first three days of the menstrual cycle

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Iranian and being single; age range between 18-25 years; education in fields except medical science; female students studying in Iranshahr velayat university dormitories; Having the characteristics of primary dysmenorrhea(Pain period with the start a few hours before or Simultaneous of menstrual bleeding and continued for up to 72 hours); having regular menstrual periods; having menstrual periods of moderate to severe primary dysmenorrhea grade based on Wong-Baker scale picture of pain. .Exclusion criteria:Having a history of uterine problems; Continually taking certain drugs; having hormone therapy at least three months before or during the course; A special diet, such as vegetarian diets and water; Psychological stress during the last six months; professional athlete; Having coagulation disorders; High blood pressure; Liver and kidney disorders;Medical disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain and bleeding. Timepoint: Two cycles before the intervention. Method of measurement: the first and second cycles of the intervention.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBibi Maryam Mirlashari

Mashhad University of Medical Sciences

mirlm931@mums.ac.ir, marylashari@gmail.com+98 51 3859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026